Zacks Research Issues Positive Estimate for SRPT Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Zacks Research boosted their Q1 2025 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $1.98 for the quarter, up from their prior estimate of $1.80. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.09 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2026 earnings at $3.66 EPS and Q3 2026 earnings at $3.63 EPS.

Several other equities analysts also recently issued reports on SRPT. UBS Group upped their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Citigroup reduced their price target on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Barclays lowered their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Robert W. Baird reduced their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Evercore ISI lowered their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $133.34 on Monday. Sarepta Therapeutics has a 12-month low of $78.67 and a 12-month high of $173.25. The firm has a market cap of $12.74 billion, a price-to-earnings ratio of 106.67 and a beta of 0.81. The company’s 50-day moving average is $122.50 and its two-hundred day moving average is $131.48. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Institutional Trading of Sarepta Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its position in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Geode Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after purchasing an additional 44,306 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Sarepta Therapeutics by 9.2% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after purchasing an additional 63,437 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after buying an additional 37,940 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.